According to Zhitong Finance App, Tengsheng Pharmaceutical-B (02137.HK) announced that Brii Biosciences, Inc. (Tengsheng Biosciences, Inc.), a wholly-owned subsidiary of the company, has signed an intellectual property licensing and technology transfer agreement with Health Yuan Pharmaceutical Group Co., Ltd. (Health Yuan Group). According to this agreement, Health Yuan Group will obtain exclusive licenses from Tengsheng Pharma America to research, develop and commercialize BRII-693 in mainland China, Hong Kong, Macau and Taiwan (collectively known as Greater China).

Zhitongcaijing · 07/04 00:41
According to Zhitong Finance App, Tengsheng Pharmaceutical-B (02137.HK) announced that Brii Biosciences, Inc. (Tengsheng Biosciences, Inc.), a wholly-owned subsidiary of the company, has signed an intellectual property licensing and technology transfer agreement with Health Yuan Pharmaceutical Group Co., Ltd. (Health Yuan Group). According to this agreement, Health Yuan Group will obtain exclusive licenses from Tengsheng Pharma America to research, develop and commercialize BRII-693 in mainland China, Hong Kong, Macau and Taiwan (collectively known as Greater China).